Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01458119
Registration number
NCT01458119
Ethics application status
Date submitted
20/10/2011
Date registered
24/10/2011
Date last updated
2/10/2018
Titles & IDs
Public title
Open-Label Phase 3 Long-Term Safety Study of Migalastat
Query!
Scientific title
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Migalastat Hydrochloride Monotherapy in Subjects With Fabry Disease
Query!
Secondary ID [1]
0
0
2011-004800-40
Query!
Secondary ID [2]
0
0
AT1001-041
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
AT1001-041
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Fabry Disease
0
0
Query!
Condition category
Condition code
Human Genetics and Inherited Disorders
0
0
0
0
Query!
Other human genetics and inherited disorders
Query!
Metabolic and Endocrine
0
0
0
0
Query!
Metabolic disorders
Query!
Metabolic and Endocrine
0
0
0
0
Query!
Other metabolic disorders
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - migalastat hydrochloride
Experimental: Migalastat - Migalastat 150-mg capsule taken orally QOD. The median duration of exposure was 23.5 m.
Treatment: Drugs: migalastat hydrochloride
Oral capsule QOD
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Number Of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)
Query!
Assessment method [1]
0
0
An adverse event (AE) was defined as any untoward medical occurrence in a participant administered migalastat that did not necessarily have a causal relationship with the treatment. Each AE was recorded at the time of reporting; visits typically occurred every 6 months. A TEAE was defined as an AE starting on or after the first study drug administration date. Serious AEs were life-threatening or resulted in death, persistent or significant incapacitation, inpatient or prolonged hospitalization, or a congenital anomaly. The criteria for AE severity were: Mild: minimal discomfort, does not interfere with normal everyday activities; Moderate: sufficiently discomforting, interferes with normal everyday activities; Severe: prevents normal everyday activities. The number of participants experiencing TEAEs is presented for those who received migalastat treatment. A summary of serious and all other non-serious AEs regardless of causality is located in the Reported Adverse Events module.
Query!
Timepoint [1]
0
0
Baseline to End of Follow-up (30 days after the end of this 42-month study), with AE reporting occurring at each study visit, which occurred once every 6 months.
Query!
Secondary outcome [1]
0
0
Annualized Rate Of Change In The Estimated Glomerular Filtration Rate (eGFR)
Query!
Assessment method [1]
0
0
The annualized rate of change of the eGFR was assessed per participant by the slope of the simple linear regression between the observed values and the assessment times. It was calculated by using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation (eGFR [CKD-EPI]) and the Modification of Diet in Renal Disease (MDRD) equation (eGFR [MDRD]). The equations are as follows:
eGFR [MDRD] = 175 * (Serum Creatinine)^-1.154 * (Age)^-0.203 * 1.212 (if black or African American) * 0.742 (if female); eGFR [CKD-EPI] = 141 * min(serum creatinine/kappa,1)^alpha * max(serum creatinine/kappa, 1)^-1.209 * 0.993^age * 1.1018(if female) * 1.159(if black or African American), where kappa is 0.7 for females and 0.9 for males, alpha is -0.329 for females and -0.411 for males, min is minimum of serum creatinine/kappa or 1, and max is the maximum of serum creatinine/kappa or 1. The number of participants with at least a Baseline and a post-Baseline value are presented.
Query!
Timepoint [1]
0
0
Baseline, Every 6 m until the End of Study (42 m)
Query!
Eligibility
Key inclusion criteria
- Completed migalastat treatment in a previous Fabry disease protocol
- Both male and female participants were enrolled
- Age 16 years or older
- Male and female participants had to agree to use protocol-identified acceptable
contraception
Query!
Minimum age
16
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Estimated glomerular filtration rate (eGFR) in the previous study was <30
milliliters/minute/1.73 square meters (mL/min/1.73 m^2) unless there was a measured
GFR available within 3 m of the Baseline Visit that was >30 mL/min/1.73 m^2
- Had undergone, or was scheduled to undergo, kidney transplantation or was currently on
dialysis
- Pregnant or breast feeding
- Treated with another investigational drug (except migalastat) within 30 days of study
start
- Unable to comply with study requirements, or deemed otherwise unsuitable for study
entry, in the opinion of the investigator
- Had documented transient ischemic attack, stroke, unstable angina, or myocardial
infarction within the 12 m before the Baseline Visit
- Had clinically significant, unstable cardiac disease in the opinion of the
investigator
- Had a history of allergy or sensitivity to migalastat (including excipients) or to
other iminosugars
- Required treatment with Glyset (miglitol) or Zavesca (miglustat)
- Had any intercurrent illness or condition that may have precluded the participant from
fulfilling the protocol requirements
- Had a severe or unsuitable concomitant medical condition
- Had a clinically significant abnormal laboratory value and a clinically significant
electrocardiogram finding at the Baseline Visit.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
N/A
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Terminated
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
14/10/2011
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
17/02/2016
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
85
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
- Adelaide
Query!
Recruitment hospital [2]
0
0
- Parkville
Query!
Recruitment postcode(s) [1]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [2]
0
0
3050 - Parkville
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Georgia
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Illinois
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Kansas
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Massachusetts
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Michigan
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
New York
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Oregon
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Pennsylvania
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Texas
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Virginia
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Washington
Query!
Country [12]
0
0
Argentina
Query!
State/province [12]
0
0
Pilar
Query!
Country [13]
0
0
Belgium
Query!
State/province [13]
0
0
Edegem
Query!
Country [14]
0
0
Brazil
Query!
State/province [14]
0
0
Porto Alegre
Query!
Country [15]
0
0
Canada
Query!
State/province [15]
0
0
Montreal
Query!
Country [16]
0
0
Denmark
Query!
State/province [16]
0
0
Copenhagen
Query!
Country [17]
0
0
Egypt
Query!
State/province [17]
0
0
Cairo
Query!
Country [18]
0
0
France
Query!
State/province [18]
0
0
Garches
Query!
Country [19]
0
0
Italy
Query!
State/province [19]
0
0
Roma
Query!
Country [20]
0
0
Spain
Query!
State/province [20]
0
0
Barcelona
Query!
Country [21]
0
0
Turkey
Query!
State/province [21]
0
0
Ankara
Query!
Country [22]
0
0
United Kingdom
Query!
State/province [22]
0
0
London
Query!
Country [23]
0
0
United Kingdom
Query!
State/province [23]
0
0
Salford
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Amicus Therapeutics
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This was a long-term, open-label study of migalastat (123 milligrams [mg] of migalastat
[equivalent to 150 mg of migalastat hydrochloride]) (migalastat) in participants with Fabry
disease who completed treatment in a previous monotherapy trial with migalastat.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01458119
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Medical Monitor, Clinical Research
Query!
Address
0
0
Amicus Therapeutics
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01458119
Download to PDF